Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
H1 and H2 deep TMS coils · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| H1 and H2 deep TMS coils | DEVICE | - |
Inclusion Criteria: * Patients diagnosed as suffering from treatment resistant major depression Exclusion Criteria: * Other axis I diagnosis * Risk factors for convulsions * Electroconvulsive therapy (ECT) in the last 9 months * History of drug abuse in the past year
H1 and H2 deep TMS coils are investigational devices being studied for the treatment of Major Depression. They are being developed by BrainsWay Ltd. (BWAY) and are currently in Phase 1 clinical development. The treatment is a form of deep transcranial magnetic stimulation.
H1 and H2 deep TMS coils are being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The company is conducting clinical research to evaluate these coils for the treatment of Major Depression.
H1 and H2 deep TMS coils are in Phase 1 clinical development. They are investigational devices and have not been approved by regulatory authorities. One Phase 1 trial has been completed, and the devices remain under clinical investigation.
H1 and H2 deep TMS coils have been studied in one completed clinical trial, identified as NCT00445237, titled 'Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression.' This Phase 1 trial was conducted in Israel and enrolled adults with Major Depression.
H1 and H2 deep TMS coils are types of deep transcranial magnetic stimulation (TMS) coils. The completed clinical trial NCT00445237 evaluated the 'Deep Transcranial Magnetic Stimulation (TMS) H-Coil,' which is consistent with the H1 and H2 coils being studied by BrainsWay for Major Depression.